©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Apr 26, 2023; 15(4): 221-234
Published online Apr 26, 2023. doi: 10.4252/wjsc.v15.i4.221
Published online Apr 26, 2023. doi: 10.4252/wjsc.v15.i4.221
Harnessing and honing mesenchymal stem/stromal cells for the amelioration of graft-versus-host disease
Tang-Her Jaing, Division of Hematology, Oncology, Department of Pediatrics, Chang Gung Children’s Hospital, Chang Gung University, Taoyuan 333, Taiwan
Tsung-Yen Chang, Department of Pediatrics, Chang Gung University College of Medicine, Taoyuan 333, Taiwan
Chia-Chi Chiu, Department of Nursing, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
Author contributions: Jaing TH and Chang TY designed the research study; Chang TY and Chiu CC performed the research; Jaing TH and Chiu CC analyzed the data and wrote the manuscript; all authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare no competing interests.
Corresponding author: Tang-Her Jaing, MD, Chief Physician, Director, Professor, Division of Hematology, Oncology, Department of Pediatrics, Chang Gung Children’s Hospital, Chang Gung University, No. 5 Fu-Shin Street, Kwei-Shan, Taoyuan 333, Taiwan.
Received: December 15, 2022
Peer-review started: December 15, 2022
First decision: January 18, 2023
Revised: January 19, 2023
Accepted: March 21, 2023
Article in press: March 21, 2023
Published online: April 26, 2023
Processing time: 132 Days and 7.4 Hours
Peer-review started: December 15, 2022
First decision: January 18, 2023
Revised: January 19, 2023
Accepted: March 21, 2023
Article in press: March 21, 2023
Published online: April 26, 2023
Processing time: 132 Days and 7.4 Hours
Core Tip
Core Tip: This article provides insights into the use of validated mesenchymal stem/stromal cells (MSCs) as a potential treatment strategy for graft-versus-host disease (GVHD) in hematopoietic stem cell transplantation (HSCT). Current prevention and treatment options involve immunosuppression, which can hinder immune recovery and limit the graft-versus-tumor effect. By using MSCs, clinicians can effectively treat GVHD, identify high-risk patients, and stratify patients based on disease severity. Therefore, MSCs can aid in promoting engraftment, ameliorating acute GVHD, and preventing chronic GVHD, making them an attractive option for HSCT.